

March 25, 2026

Comparative and Translational Medicine and Biotechnology



Ana Colette Maurício

LAQV REQUIMTE, ICBAS, Universidade do Porto, Portugal
acmauricio@icbas.up.pt; ana.colette@hotmail.com
https://sigarra.up.pt/icbas/pt/func_geral.formview?p_codigo=413661

The Regenerative Medicine multidisciplinary research group is dedicated to advancing Comparative and Translational Medicine and Biotechnology. Its primary objective is to deliver cutting-edge scientific research and postgraduate training in Tissue Engineering, with a focus on cellular therapies and biomaterials for disease treatment within the framework of Advanced Therapy Medicinal Products (ATMPs). This goal is pursued through a distinctive integration of hands-on research that brings together academia, clinicians, and industry partners. Within this context, the group develops diverse tissue-repair strategies across multiple diseases using a One Health approach. By identifying therapeutic solutions in Veterinary Medicine, the group contributes to the generation of knowledge that strengthens both clinical and pre-clinical research pipelines for Human Medicine. A second major objective is to advance One Health by deepening scientific understanding of Animal Cell-Based Therapies and Medical Devices for Regenerative Medicine with translational potential for human applications. This is supported by robust and effective knowledge-transfer mechanisms. All research activities fall within the broader field of Regenerative Medicine. Ongoing funded projects also provide a strong foundation for the development of PhD, Master's, and Bachelor's theses, reinforcing the group's commitment to high-level training and scientific innovation.

Short Bio

Ana Colette Maurício, Full Professor at ICBAS – University of Porto, holds a Pre-Bologna degree in Veterinary Medicine (1995), a PhD in Veterinary Sciences (1999), and Aggregation in Veterinary Sciences (2011). Her scientific career began in leading physiology and biophysics laboratories at the Instituto Gulbenkian de Ciência, Universidade Nova de Lisboa, and the Albert-Ludwigs Universität Freiburg, where she developed expertise in electrophysiology, ion transport, cell manipulation, and reproductive physiology—foundations that later supported her transition into regenerative medicine.

Since 2003, she has built a multidisciplinary research program in regenerative medicine, tissue engineering, and cell-based therapies, focusing on mesenchymal stem/stromal cells, biomaterials, and advanced biomanufacturing for bone, nerve, skin, vascular, and muscle regeneration. She leads the Regenerative Medicine and Experimental Surgery group, now integrated in LAQV-REQUIMTE, and has coordinated or participated in over 30 national and European R&D projects, including DGAV/ORBEA-authorized *in vivo* studies and FDA-oriented preclinical dossiers.

Her translational work generated patents and trademarks—such as Regenera® and CellSecret™—and culminated in the creation of Regenera Sciences Corp, USA, and an U.Porto spin-off dedicated to regenerative therapies. With more than 160 indexed publications, eight edited books, and supervision of over 55 PhD theses (completed and ongoing), she is internationally recognized for advancing regenerative medicine within a One Health framework.

Acknowledgements

The author acknowledges the Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA), Porto University (UP), Regenera Sciences Corp (USA) and Fundação para a Ciência e Tecnologia (FCT) for the funding and availability of all technical, structural, and human resources necessary for the development of this work. This work was supported by national funds through FCT under the projects LA/P/0059/2020 and REQUIMTE-Laboratório Associado para a Química Verde (UID/50006/2023), funded by FCT and the Ministério da Educação, Ciência e Inovação (MECI).

Webinar Host

Ana Rita Duarte, Bio(chemical) Process Engineering Group